Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|July 17, 2015
PDA Education Course: Establishment of a Risk Based Environmental Monitoring Program
This podcast will feature the instructor of PDA’s new Education course, Establishment of a Risk-Based Environmental Monitoring Program, to be offered September 11, 2015 at PDA’s Training and Research Institute, located in Bethesda, MD. This course will present information on the establishment of a risk based environmental monitoring (EM) program, covering both the establishment of new EM programs as well as reassessment of current EM programs to ensure they are in compliance with industry standards. The goal is for participants to understand the tools available for conducting EM risk assessments and how to properly use them to create risk-based EM programs.
This podcast will feature the instructor of PDA’s new Education course, Establishment of a Risk-Based Environmental Monitoring Program, to be offered September 11, 2015 at PDA’s Training and Research Institute, located in Bethesda, MD.
This course will present information on the establishment of a risk based environmental monitoring (EM) program, covering both the establishment of new EM programs as well as reassessment of current EM programs to ensure they are in compliance with industry standards. The goal is for participants to understand the tools available for conducting EM risk assessments and how to properly use them to create risk-based EM programs.
The course format includes small group breakouts for completion of EM risk assessments.
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.